Related Experiment Video
Updated: Jun 7, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 Protects lung cancer cells against metabolic stress
Chompunoot Sinthupibulyakit1, Wanida Ittarat, William H St Clair
1Graduate Center for Toxicology, University of Kentucky, Lexington, KY 40536, USA.
Abstract:
The preferential use of aerobic glycolysis for energy production by cancer cells, a phenomenon known as the 'Warburg effect', is well recognized and is being considered for therapeutic applications. However, whether inhibition of glycolysis will be effective in all types of cancer is unclear. The current study shows that a glycolytic inhibitor, 2-deoxy-D-glucose (2DG), exhibits the cytotoxic effect on non-small cell lung cancer in a p53-dependent manner. 2DG significantly inhibits ATP production in p53-deficient lung cancer cells (H358) but not in p53-wt cells (A549). In contrast to p53-wt cells, p53-defective cells are unable to compensate for their need of energy via oxidative phosphorylation (OXPHOS) when glycolysis is inhibited. In the presence of p53, increased ROS from OXPHOS increases the expression of p53 target genes known to modulate metabolism, including synthesis of cytochrome c oxidase 2 (SCO2) and TP53-induced glycolysis and apoptosis regulator (TIGAR). Importantly, 2DG selectively induces the expression of the antioxidant enzymes manganese superoxide dismutase (MnSOD) and glutathione peroxidase 1 (GPx1) in a p53-dependent manner. The results demonstrate that the killing of cancer cells by the inhibitor of glycolysis is more efficient in cancer cells without functional p53 and that p53 protects against metabolic stress by up-regulation of oxidative phosphorylation and modulation of antioxidants.
Insights
The glycolytic inhibitor 2-deoxy-D-glucose (2DG) shows cytotoxicity in non-small cell lung cancer cells. This effect is p53-dependent, with p53-deficient cells being more susceptible to 2DG treatment.
Area of Science:
- Oncology
- Cancer Metabolism
- Molecular Biology
Background:
- The Warburg effect, preferential aerobic glycolysis in cancer, is a therapeutic target.
- The efficacy of inhibiting glycolysis across all cancer types remains uncertain.
Purpose of the Study:
- To investigate the cytotoxic effect of the glycolytic inhibitor 2-deoxy-D-glucose (2DG) on non-small cell lung cancer (NSCLC).
- To determine the role of p53 in mediating the response to 2DG in NSCLC.
Main Methods:
- Treatment of p53-deficient (H358) and p53-wild-type (A549) NSCLC cells with 2DG.
- Assessment of ATP production and oxidative phosphorylation (OXPHOS) capacity.
- Analysis of reactive oxygen species (ROS) levels and expression of p53 target genes and antioxidant enzymes.
Main Results:
- 2DG significantly inhibited ATP production in p53-deficient cells but not in p53-wild-type cells.
- p53-wild-type cells compensated for inhibited glycolysis via OXPHOS, unlike p53-deficient cells.
- p53-dependent induction of antioxidant enzymes (MnSOD, GPx1) and metabolic regulators (SCO2, TIGAR) was observed.
Conclusions:
- The cytotoxic effect of 2DG is more efficient in cancer cells lacking functional p53.
- p53 protects cancer cells against metabolic stress induced by glycolytic inhibition through enhanced OXPHOS and antioxidant defense.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Negative Regulator Molecules
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Intrinsic Apoptotic Pathway
